Abstract
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape
for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia
(R/R B-ALL). However CAR T-cell therapy of R/R T-ALL has unique challenges, such as
the lack of specific tumor antigens, cell fratricide and T cell aplasia, in comparison
with that of R/R B-ALL. Despite promising therapeutic outcomes in R/R B-ALL, application
of this therapy is limited by high relapse rates and immunological toxicities. Recent
studies suggest patients who underwent allogeneic hematopoietic stem cell transplantation
post-CAR T-cell therapy would achieve durable remission and better survival, but this
remains controversial. Herein, I briefly review published data on the clinical use
of CAR T-cells in treating ALL.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acute lymphoblastic leukemia: a comprehensive review and 2017 update.Blood Cancer J. 2017; 7e577
- Acute lymphoblastic leukaemia.Lancet. 2020; 395: 1146-1162
- Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.Cancer. 2010; 116: 5568-5574
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.Blood. 2012; 120: 2032-2041
- The myth of the second remission of acute leukemia in the adult.Blood. 2013; 121: 1077-1082
- Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.N Engl J Med. 2016; 375: 740-753
- Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.N Engl J Med. 2017; 376: 836-847
- Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?.Leuk Lymphoma. 2020; 61: 7-17
- Are CAR T cells better than antibody or HCT therapy in B-ALL?.Hematol Am Soc Hematol Educ Program. 2018; 2018: 16-24
- CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.Blood Adv. 2019; 3: 3539-3549
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Cancer. 2013; 119: 2728-2736
- Chimeric antigen receptor T-cell therapy for the community oncologist.Oncologist. 2016; 21: 608-617
- Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Hematol Am Soc Hematol Educ Program. 2012; 2012: 143-151
- Cancer cell therapies: the clinical trial landscape.Nat Rev Drug Discov. 2020; 19: 583-584
- CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?.Stem Cell Res Ther. 2021; 12: 527
- Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.Best Pract Res Clin Haematol. 2021; 34101305
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.Blood. 2011; 118: 4817-4828
- Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med. 2014; 6: 224ra25
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014; 371: 1507-1517
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385: 517-528
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Investig. 2016; 126: 2123-2138
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood. 2017; 129: 3322-3331
- Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med. 2018; 378: 439-448
- Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med. 2018; 378: 449-459
- Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL.Blood. 2019; 134: 2361-2368
- Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia.J Clin Oncol. 2020; 38: 415-422
- Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.Lancet Haematol. 2020; 7: e816-e826
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.Blood. 2015; 125: 4017-4023
- Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.Blood Adv. 2020; 4: 2325-2338
- HESTER: a phase II study evaluating efficacy and safety of tisagenlecleucel reinfusion in pediatric and young adult patients with acute lymphoblastic leukemia experiencing loss of B-cell aplasia.Blood. 2020; 136: S23-S24
- Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments.Front Immunol. 2021; 11569117
- Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.Ann Hematol. 2021; 100: 1003-1012
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).Ann Oncol. 2022; 33: 259-275
Article info
Publication history
Published online: February 24, 2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
